03:53 PM EDT, 08/01/2024 (MT Newswires) -- IRadimed ( IRMD ) shares fell 1.3% in recent trading Thursday after the company posted higher Q2 results.

reported Q2 non-GAAP net income Thursday of $0.42 per diluted share, up from $0.36 a year earlier.

Two analysts polled by Capital IQ expected $0.37.

Revenue for the quarter ended June 30 was $17.9 million, up from $16.1 million a year earlier.

Two analysts surveyed by Capital IQ expected $17.7 million.

For Q3, IRadimed ( IRMD ) anticipates non-GAAP diluted EPS of $0.38 to $0.41 on revenue of $18 million to $18.2 million. Analysts surveyed by Capital IQ expect EPS of $0.38 on revenue of $18 million.

For full-year 2024, the company continues to expect non-GAAP diluted EPS of $1.52 to $1.62 on revenue of $72 million to $74 million. Analysts polled by Capital IQ expect EPS of $1.53 on revenue of $72.5 million.

Price: 46.10, Change: -0.61, Percent Change: -1.31